<DOC>
	<DOC>NCT00983658</DOC>
	<brief_summary>This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety, and tolerability of huMAb OX40L administered to patients by IV infusion for the treatment of allergen-induced asthma.</brief_summary>
	<brief_title>A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Airway Obstruction</mesh_term>
	<criteria>Weight between 50 and 125 kg Mild, stable allergic asthma History of episodic wheeze and shortness of breath FEV1 at baseline ≥ 70% of the predicted value For women of childbearing potential, agreement to use an effective means of contraception while enrolled in the study For men with partners of childbearing potential, willingness to use condoms with spermicide during treatment Ability to comprehend and follow all required study procedures Positive skin prick test to common aeroallergens (e.g., cat, dust, mite, grass, and pollen) Positive allergeninduced early and late airway bronchoconstriction A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry Acute infection (including viral infection) within the 6 weeks preceding dosing (8 weeks for respiratory infections) or any ongoing chronic infection History of recurrent bacterial infection as an adult or history or presence of any chronic infectious condition, including (but not limited to), tuberculosis, parasitic infection, etc. Lung disease other than mild allergic asthma History of heart, lung, kidney, liver, neurologic or chronic infectious disease Concomitant disease or condition, which could interfere with the conduct of the study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease History of serious adverse reaction or hypersensitivity to any drug Pregnancy or lactation or positive serum pregnancy test at screening Chronic use of any other medication for treatment of allergic lung disease other than shortacting β2agonists or ipratropium bromide Current (or history of) treatment with a monoclonal antibody or chimeric biomolecule within the past 5 months (5 halflives of the drug), including omalizumab Regular use of tobacco products of any kind or within the previous 6 months, or smoking history &gt; 10 packyears</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Anti-OX40L</keyword>
	<keyword>Mild Allergic Asthma</keyword>
	<keyword>Allergies</keyword>
	<keyword>Allergic Asthma</keyword>
	<keyword>Adult Asthma</keyword>
</DOC>